The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Factors to consider when treating AML and the importance of communicating with patients
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares his opinion on the goal of treatment in acute myeloid leukemia (AML), highlighting factors to consider when treating patients, and the importance of discussing and communicating with patients to better understand what is best. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
